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Ketamine as a Treatment Modality for TreatmentResistant Depression
Abstract
Many recent studies have demonstrated the ability of ketamine, an NMDA receptor antagonist,
to produce antidepressant effects that may be effective in helping reduce treatment-resistant
major depression. In particular, three double-blinded randomized control trials have been
conducted to assess the viability and effectiveness of this medication for treatment. This
systematic literature review will analyze these studies and determine if the overall research
indicates that ketamine is useful in improving depression as measured by the Montgomery–
Asberg Depression Rating Scale (MADRS)1.
Objective: Assess the effectiveness of IV Ketamine in reducing treatment-resistant major
depressive disorder as measured by the Montgomery–Asberg Depression Rating Scale
(MADRS)1.
Design: Systematic literature review of three randomized control trials
Methods: Searches were done in PubMed utilizing the terms ketamine, depression, treatmentresistant depression, MADRS, placebo, and Montgomery-Asberg. In PubMed the following limits
and terms were used: published in the last 10 years, humans, randomized controlled trial, adults
>19 years, and English.
Results: Search criteria found three randomized control trials (RCTs) that met the
inclusion/exclusion criteria: Fava et al (2018)2, Murrough et al (2013)3, and Phillips et al (2019)4.
Fifteen additional trials were excluded based on the following: trials using esketamine (2), ones
analyzing confounding variables (6), using polypharmacy (1), non-applicable studies using
search terms (4), or non-blinded (1), and duplicate results (1).
Conclusion: All studies found that ketamine infusions resulted in statistical improvement on the
MADRS scale among the trials’ 213 participants in total. Each of the three trials administered
ketamine at subanesthetic doses, and they all demonstrated effectiveness. While each of the
studies showed improvement over placebo, they also showed improvement when compared to
midazolam, and short-acting benzodiazepine. While the improvements were all noted at the 24hour mark after administration, further study is needed to determine long-term effectiveness and
safety.

Introduction
In the United States, depression is a serious issue that affects a significant portion of the
population. According to the National Institute of Mental Health, an estimated 17.3 million adults
in the United States had at least one major depressive episode (7.1% of all U.S. adults in
2019)5, 6. 65% of these patients received treatment with medication as well as counseling.
However, a significant portion of these patients still are unable to reach adequate response to
these treatments. These patients are at high risk for many conditions. Not only do treatmentresistant states lead to higher rates of suicide, but they also increase risk of somatic complaints,
heart disease, and obesity7. This can increase lifetime costs of care, as well as decreasing
overall lifespan7. They are twice as likely to be hospitalized for depression. Patients with
treatment-resistant depression have over 6 times the mean total medical costs of nontreatment-resistant depressed patients ($42,344 vs. $6512)7.
Treatment-resistant depression (TRD) typically refers to inadequate response to at least one
antidepressant trial, given standard doses and duration8. It is a relatively common occurrence,
with 50-60% of the patients not achieving remission following antidepressant treatment. While
there is not a standard definition of “adequate response”, measuring tools such as the
Montgomery–Asberg Depression Rating Scale (MADRS) are used to monitor changes in patient
mood and depression levels. The Montgomery–Asberg Depression Rating Scale (MADRS)1
scores depression levels based on ten categories, with each category scored between 0-6. It
was designed to more closely monitor the changes in mood with antidepressant treatment.
While there are many categories of antidepressant medications, ketamine provides a novel
approach to treatment. As a noncompetitive N-methyl-D-aspartate (NMDA) receptor antagonist,
it blocks HCN1 receptors. It also binds to the opioid mu and sigma receptors at higher dosage
levels. While the exact mechanism of ketamine’s effects on depression is unknown, there are
several prevailing theories. Some propose that ketamine reverses burst activity and theta-band
synchronization in the lateral habenula. Others postulate that ketamine also may generate its
antidepressant effects indirectly by blocking NMDA receptors on GABA interneurons.
This review aims to investigate IV ketamine as a safe and effective treatment for treatmentresistant depression. In particular, three double-blinded randomized control trials have been
conducted to assess the viability and effectiveness of this medication for treatment. This
systematic literature review will analyze these studies and determine if the overall research
indicates that ketamine is useful in improving depression as measured by the Montgomery–
Asberg Depression Rating Scale (MADRS).

PRISMA flow diagram: Searches were done in PubMed utilizing the terms ketamine,
depression, treatment-resistant depression, MADRS, placebo, and Montgomery-Asberg.

Study Results
Study 1:
Antidepressant Efficacy of Ketamine in Treatment-Resistant Major Depression: A Two-Site
Randomized Controlled Trial 3
Objective:
This study compares the usage of ketamine against placebo in the treatment of adults, looking
at if ketamine is both efficient and rapid at producing depression remission.
Study design:
This study compared two different treatments (ketamine and midazolam). Midazolam was used
as the placebo in this study. It was a two-site, parallel-arm, randomized controlled trial of a
single infusion of ketamine. During a two-year period, patients deemed eligible for the study
were screened and disqualified if they were outside of the age range (21-80), had comorbid
psychiatric conditions such as bipolar, were taking contraindicated medications, or had a mini
mental status exam of <27. Each patient had a physical examination, routine hematologic and
biochemical tests, urine toxicology measurements, and an electrocardiogram (ECG) to screen
out substance use or possible confounding medical conditions. In total, the study utilized 72
individuals.
This study randomly assigned patients (in a 2:1 ratio) to either a ketamine or a midazolam
group. The patients received a single intravenous infusion of ketamine hydrochloride (0.5
mg/kg) or midazolam (0.045 mg/kg) infused over 40 minutes. The drug vial was masked so that
all were blinded to the treatment group until the point of analysis.
Patients were monitored from 240 minutes following the start of the infusion until discharge 24
hours after time of infusion. They then received outpatient evaluations 48 hours, 72 hours, and 7
days post infusion. Nonresponders were considered patients with less than 50% improvement
from baseline (using the MADRS score). Nonresponders 7 days after the infusion were
considered failures and not-followed further. Those who had a positive response were followed
biweekly until relapse or for an additional 4 weeks, whichever came sooner.
Study Results:
Patients in the ketamine group had significantly greater improvement in the MADRS score at 24
hours than the midazolam group. After adjustment for baseline scores and site, the mean
MADRS score was lower in the ketamine group than in the midazolam group by 7.95 points
(95% confidence interval [CI], 3.20 to 12.71), corresponding to a Cohen’s d of 0.81. MADRS
scores at 24 hours did not differ as a function of site (F=0.63, df=1, 70, p=0.43). The NNT was
determined to be 2.8.
Both of the treatment groups demonstrated a small worsening in MADRS scores for every
additional day postinfusion (95% CI, 0.00009 to 0.00062). Overall, patients in the ketamine
group had lower MADRS scores (mean, 16.93; 95% CI, 14.03 to 19.82) than patients in the
midazolam group (mean, 23.19; 95% CI, 19.03 to 27.34).

Study Critique
While this study used midazolam as a placebo due to the similar appearing effects on the
patient, no true placebo was used. While it may be useful due to both the patient and provider
seeing physical results of administration, it also adds confounding variables as midazolam may
have some unexpected benefit. Adding a third inert group would have reduced this problem.

Study 2
Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive
therapy in treatment-resistant depression 2
Objective:
The purpose of this study was to compare the effects of various dosages of ketamine against a
midazolam placebo in improving short-term symptoms of depression.
Study Design:
This study was a double-blinded RCT. It was conducted across six US academic sites, and all
patients were treated as outpatients. Participants were 18–70 years old with treatment resistant
depression. 99 eligible subjects were randomly assigned to one of the five arms in a 1:1:1:1:1
fashion.
The categories included 4 groups who received various dosages of intravenous ketamine, as
well as a single group who received midazolam at 0.045 mg/kg (n=19). The ketamine group
dosages were as follows: 0.1 mg/kg (n = 18), 0.2 mg/kg (n = 20), 0.5mg/kg (n = 22), and
1.0 mg/kg (n = 20).
Each of the groups were screened with multiple depression rating scales ((HAM-D-6, MADRS,
SDQ, PAS, CGI-S, and CGI-I) and were followed at 0, 1, 3 5, 7, 14, and 30 days to assess the
safety and efficacy. For efficacy. Day 3 was determined to be the endpoint, but the patients
were followed for an additional 30 days to determine benefit length.
Study Results:
On day 3, the MADRAS test was repeated. The results indicated a strong improvement for the
0.5 mg/kg ketamine group (p= 0.02, CI−16.56, −3.15). The primary screening tool, the HAM-D-6
assessment, showed 2 groups had statistically significant improvement on Day 1: the .5 mg/kg
and the 1.0 mg/kg dose. The 0.5 mg/kg group had an adjusted p value of 0.00 (CI −7.35, −2.24),
and the 1.0mg/kg ketamine group had an adjusted p value of 0.04 (CI −6.37, −1.15).
Only two of the other assessments besides the HAM-D-6 and the MADRAS showed statistically
significant data. Statistical significance of the group × time interaction effect (considered their
secondary outcome) was only achieved for the SDQ (p = 0.0105) and the PAS (p = 0.0341) in
the 5-group comparison, and the PAS (p = 0.0332) and the CGI-S (p = 0.0204) in the 2-group
comparison.
Additionally, side effects for all the groups given ketamine were higher. Headache (11.3% vs.
0%), nausea (10% vs. 0%), vomiting (5% vs. 0%), and depression (3.8% vs. 0%) were all higher
in the ketamine groups vs the midazolam group. Additionally, 2 reported suicidal ideation in the

ketamine groups, while 0 did in the midazolam group. While overall the testing revealed
depression improved, the self-reported increase in depression is important to note.
Study Critique:
One critique of this study is that they allowed patients to continue benzodiazepine usage if they
were deemed stable on it for >4 weeks. This factor was not accounted for in the results, and a
subgroup analysis would have been appropriate. Additionally, the MADRAS test was not
administered on Day 1. As such, data was only listed for Day 3 for this group. While multiple
measures were used, not all data from each group for each survey type was listed. This
perhaps could indicate that the study only chose the survey types that showed a consistently
positive result.
Secondly, at least four patients did not receive the dose indicated for their treatment group.
Each of the four was underdosed, and each was due to an error in calculation. While each of
these was reported, it may indicate a larger problem with the study.
Another possible confounding factor for the results was the ability of both clinicians and the
participants to correctly guess if they had been given ketamine. For the two statistically
significant groups (0.5 mg/kg and 1.0 mg/kg), both groups had extremely high correct guess
(100% of clinicians and 77% for the 0.5mg/kg group, and 95% for both for the 1.0mg/kg group).
This functional unblinding may have altered perceptions of improvement.
Additionally, this study did not publish the full results. Raw numbers are omitted and
percentages used instead. P values are only given for some of the data. By omitting the raw
data, it is impossible for full comparisons to be made.
Finally, there was some disparity in the groupings themselves. In the group where ketamine was
administered at 0.2mg/kg, whites were the only racial group present. 98% of the women in the
study were in just two groups: the midazolam group and the 1.0 mg/kg group. These disparities
pose a problem, as the study was comparing the doses as well as the drug. As such, drastically
different groups can pose a problem for application to wider populations.

Study 3:
Single, Repeated, and Maintenance Ketamine Infusions for Treatment-Resistant Depression: A
Randomized Controlled Trial 1
Objective:
This study evaluates the effects of a single ketamine infusion, a series of repeated ketamine
infusions, and maintenance ketamine fusions.
Study Design:
This study was a double-blinded RCT that prescreened sixty-three individuals (age range of 1865) for treatment-resistant depression by consultation with a study physician. They met the
DSM-IV-TR criteria for major depressive disorder, single or recurrent episodes without psychotic
features, confirmed with a mini-international neuropsychiatric interview. The inclusion criteria

was a score of 25 or more on the MADRS at screening and at randomization, with no more than
20% improvement between these visits. They also must have had at least psychotropic
medication treatment for at least 6 weeks without any changes to their treatment during the trial.
Exclusion criteria include a history of drug abuse or dependence, BMI of 35 or higher, history of
mania or hypomania, and any unstable medical conditions.
Forty-six of the participants went through formal screening and forty-one participants went on to
complete the study. The study was broken down into a three-phase clinical trial and positive
response to ketamine was defined as a 50% or more decrease in MADRS from baseline (prior
to start of phase 1).
In phase 1, the goal was to test the efficiency of ketamine compared to midazolam (the placebo,
a short-acting benzodiazepine). Participants were randomly assigned in a 1:1 ratio to receive a
dose of ketamine hydrochloride (0.5 mg/kg, diluted in 0.9% sale over a 40 minute IV pump) or
midazolam (30 ug/kg, for 2 mg diluted in saline). The infusions were at least 7 days apart and
they had to return to 80% of their baseline MADRS score before getting the other infusion, and
phase 2. The medication bags were labeled drug A and drug B by an independent
randomization. The study personnel and participants were debriefed after study completion.
In phase 2, the goal was to test the effects of repeat ketamine after relapse. The participants
received six open-labeled ketamine infusions, administered three times a week, for 2 weeks.
Participants who had at least a 50% improvement in MADRS score moved to phase 3. In phase
3, the goal was to observe the effects of maintenance ketamine when the frequency of infusions
decrease from phase 2. The participants received ketamine infusions once weekly for four
weeks. In both phase 2 and 3, the MADRS score was measured throughout the course of
infusions. Follow up measures were obtained three days after the final infusion for each phase
by study physicians.
Study results:
In phase 1, forty-one participants received the two infusions on an average of 10 days apart
(range 7-36 days) and no difference in time gap between those who received one or the other
drug first. The results show a significantly lowered MADRS total score after each ketamine
infusion (mean decrease of 10.9 points) compared with midazolam infusion (mean decrease of
2.8 points), even after adjusting for baseline MADRS score, and order of drug administration.
Twenty-four hours post ketamine infusion, 11 participants met antidepressant response criteria
and 2 met remission criteria, but none met antidepressant response with midazolam in phase 1.
In phase 2, only thirty-nine completed from the forty-one participants. In the follow up visits,
twenty-three participants met antidepressant response and 9 met remission. Responders had a
mean decrease of 21.6 points in MADRS total score and nonresponders had a 3.1 point
decrease.
In phase 3, 23 participants were included. All of the participants in this phase had at least a 50%
improvement in their MADRS scores in the prior phase. Phase 3 was designated the
maintenance phase. All participants were given once weekly ketamine doses, although no
statistically significant improvement was noted in phase 3 (p=0.49). This indicates no further
improvement after phase 2 levels.

Study critique:
The biggest critique of this study was that Phase 2 and 3 were open label, and thus lost the
benefits of blinding on the data. While Phase 1 was double blinded, the lack of any blinding in
the other phases may contribute to the assessment scoring.
A secondary limitation of this study was the fact that participants were continued on their current
medication treatment throughout the study. The data did not separate these participants, so it is
possible that the treatment is interacting in a way with the current medications that would be
different from an otherwise unmedicated person. As such, the study results can only be read as
ketamine being a useful adjunct, but not as primary treatment.
The study was fairly small, with only 41 participants (with only 23 continuing until phase 3). The
small nature of this study impairs its ability for the results to be extrapolated to the larger
population without additional studies.

Discussion
Major depression is a disease that affects millions in the United States alone. Current
treatments have a poor success rate. Unsuccessfully treated depression leads to decreased
overall health and risk of death to the patient, as well as costing the healthcare system millions
of dollars. Ketamine, a medication often used for sedation and pain, has shown some promise
in the treatment of depression. The purpose of this review is to determine whether ketamine,
when compared against placebo, is effective at reducing treatment resistant depression.
An overview of the three studies is provided below (Table A). While each of the studies used the
MADRS scale to determine the patient’s subjective improvement at the 72-hour post
administration mark, each of the papers had a slightly different focus. Murrough et al. followed
the patients at the 1, 2, 3, and 7 day marks (with biweekly follow up until relapse or one month),
and was focused on determining whether NMDA antagonists were likely to be effective as a
treatment for depression. Maurizo et al. also compared the effectiveness of different dosages of
ketamine, although it used the HAM-D-6 as the primary depression reporting tool, while only
utilizing the MADRS on day 3 and not after 24 hours. Phillips et al. was unique in that it used
multiple infusions over the course of the trial.
All three studies found significant improvement on the MADRS for ketamine (see table B),
although Maurizo et al. found the significance only in the 0.5mg/kg and 1.0mg/kg ketamine
dosages. This is notable for Murrough et al. and Phillips et al. also using the 0.5mg/kg dosage.
As such, all three studies show significant improvement at the 0.5mg/kg dosage level, especially
at the 24 hr mark (although Maurizo et al was using the HAM-6-D at that point). At the 72 hr
common time mark, all three trials showed an improvement in scores utilizing the MADRS when
comparing ketamine to placebo.

Total

Murrough et al

Phillips et al

Maurizo et al

73

41

99

Patients, N
Age Range

21-80

18-65

18-70

Study Type

Double blinded RCT

Double-blinded (phase 1 only)
RCT

Double-blinded
RCT

Intervention

Single Ketamine hydrochloride
0.5 mg/kg IV infusion

3 phases of Ketamine
hydrochloride 0.5 mg/kg (0.9%
saline) IV infusions

Single IV
infusion of
Ketamine 0.1
mg/kg,
Ketamine 0.2
mg/kg,
Ketamine 0.5
mg/kg,
or Ketamine 1.0
mg/kg

Control

Single Midazolam 0.045 mg/kg
IV infusion

SIngle Midazolam 0.03 mg/kg for
2mg (diluted in saline) IV infusion

Single
Midazolam
0.045 mg/kg IV
infusion

MADRS
measurement
time

24 hours postinfusion.
Outpatient evaluation includes
48 hours, 72 hours, and 7 days
postinfusion. Reponsders
followed biweekly until relapse
or for 4 more weeks, whichever
earlier.

Phase 1: 2 hours, 24 hours, 7
days postinfusion

Day 3 after
infusion.

Phase 2: Throughout the course
of 6 infusions
Phase 3: Throughout the course
of 4 infusions

Table A: Comparing the 3 studies reviewed in this article.

While each of the studies showed improvement at the 24 hour mark, it remains to be seen if the
effect is lasting, or if (and how often) the treatment needs to be repeated. Murrough et al used a
single dose to determine the effects through day 7. Maruizo et al followed up until day 30, where
improvements against placebo were still evident. While the Phillips study had three phases that
continued the timeline of monitoring longer, both of the later phases lost blinding, which reduces
the applicability of comparison.
An important factor in whether ketamine treatment will be effective is the level of unwanted side
effects. While the Phillips trial tracked and reported side effects using both the e Systematic
Assessment for Treatment Emergent Events and the Clinician-Administered Dissociative States
Scale, no serious adverse effects were noted. However, they did report side effects such as
short-term elevation in blood pressure, cardiorespiratory effects, numbness or tingling,
dissociation, dizziness, and visual disturbances. In the Maurizo study, headache, nausea, and
vomiting were statistically higher effects than their midazolam placebo group. In that same
study, there were also two more serious adverse events: one patient in the 0.2mg/kg ketamie
group committed suicide during the trial, and another had abnormally high hepatic function

results. The Murrough study used the Patient Rated Inventory of Side Effects, the ClinicianAdministered Dissociative States Scale, and the Brief Psychiatric Rating Scale positive
symptom subscale, and found that blurred vision and poor concentration were more frequently
reported in the ketamine group than the midazolam one. Of note, that study also found a
correlation to increased blood pressure relating to higher doses of ketamine. These effects
would have to be taken into account before treating patients, especially for longer term and at
higher dosages.
Patients, N

P value

Mean MADRS
decrease

Response
Rate
(response +
remission)

SD

73

P<0.001

7.95

64%

NA

Phillips et al

Phase 1: 41

Phase 1:
P<0.001

Phase 1: 10.9

Phase 1:
31.71%
(13/41)

Phase 1: 8.9

3 phases of
Ketamine
hydrochloride 0.5
mg/kg (0.9%
saline) IV infusions

Phase 2: 39

Murrough et al

Single Ketamine
hydrochloride 0.5
mg/kg IV infusion

Phase 2:
P<0.001

Phase 2: 21.6
(responders),
3.1 (responders)

Phase 3:

Phase 3: 0

Phase 3: 23

P=0.49

Phase 2:
82.05%
(32/39)

Phase 2: 5.8
(responders), 5.7
(nonresponders)

Phase 3: 0
Phase 3:
91.30%
(21/23)

Maurizo et al

99

Ketamine 0.1
mg/kg,

Ketamine
0.1 mg/kg:
18

Ketamine 0.2
mg/kg,
Ketamine 0.5
mg/kg,
Ketamine 1.0
mg/kg,
or Midazolam
0.045 mg/kg

Ketamine
0.2 mg/kg:
20
Ketamine
0.5 mg/kg:
22
Ketamine
1.0 mg/kg:
20
Midazolam

Ketamine
0.5mg/kg:

Ketamine 0.1
mg/kg: 33.8%

Ketamine 0.1
mg/kg: 31%

Ketamine 0.1
mg/kg: 5.9

Raw p:
0.00

Ketamine 0.2
mg/kg: 34.5%

Ketamine 0.2
mg/kg: 21%

Ketamine 0.2
mg/kg: 8.5

Ketamine 0.5
mg/kg: 31.6%

Ketamine 0.5
mg/kg: 59%

Ketamine 0.5
mg/kg: 3.9

Ketamine 1.0
mg/kg: 32.7%

Ketamine 1.0
mg/kg: 53%

Ketamine 1.0
mg/kg: 5.9

Midazolam

Midazolam

Midazolam 0.045

Adj. p:
0.02

0.045
mg/kg: 19
Table B: Statistical breakdown of study data

0.045 mg/kg:
33.6%

0.045 mg/kg:
33%

mg/kg: 7.1

Conclusion
In patients 18-65 years old with treatment-resistant depression, does ketamine reduce
psychological distress compared to standard depression medication or placebo, as measured
on the MADRS depression scale.

Intravenous ketamine, particularly at the 0.5mg/kg-1.0mg/kg dosages, is effective at improving
feelings of depression in adult patients with a diagnosis of Major Depressive Disorder who are
non-responsive to standard treatment. While short-term effectiveness and safety appear to be
positive, more research is needed to determine long-term efficacy and need for repeat
treatments.
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